Research on influenza vaccine immunogencity in infants.

Research on influenza vaccine immunogencity in infants. - Research on influenza vaccine immunogencity in infants.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000241

Enrollment

200

Registered

2005-09-22

Start date

2005-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

influenza

Interventions

Influenza HA vaccine is inoculated twice at 4 weeks interval. Side reaction survey at 48hours after vaccination and survey during epidemics of influenza are conducted. Inoculated dose: 0.1 mL for in

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Infants who visit a medical institution to have vaccination and who fulfill all of the following criteria: 1.Healthy infants under 4 years old at the time of acquisition of consent. 2.Infants whose acceptable representatives consent to participate in this research in written.

Exclusion criteria

Exclusion criteria: 1.Infants with a fever at the time of planned vaccination. 2.Infants with serious acute diseases. 3.Infants who has induced anaphylaxis by the substances of the vaccine. 4.Infants considered inappropriate to be inoculated vaccine.

Design outcomes

Primary

Measure	Time frame
HI titers before and after vaccination.	—

Secondary

Measure	Time frame
Survey on side reaction after vaccination. Survey during epidemics of influenza.	—

Countries

Japan

Contacts

Public ContactShin Irie

Medical Co. LTA Kyusyu Clinical Pharmacology Research Clinic Clinical Pharmacology Department

092-733-1001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026